Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE PetVivo Holdings, Inc.
NEW YORK, Aug. 12, 2014 /PRNewswire/ -- PetVivo Holdings, Inc. (OTCQB: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics.
The company intends to leverage other company's investments in the human bio-materials and medical device industries to commercialize them for pets. PetVivo's strategy is to in-license proprietary products from human medical device companies specifically for use in pets. The key to making this strategy work is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently scrutinized products for human use. The first product for PetVivo, Inc., a PETV subsidiary, is patented in the US and has been accepted for patent approval in Canada.
US patent application number 12/700,896 entitled "Protein Matrix Materials, Devices and Methods of Making and Using Thereof" and recent study results have initiated an analyst report below.
A full report on PETV that includes fundamental data, company background, review of current business model, competition breakdown, analyst summary and risk factors can be viewed by using the following link:
Copy and paste to browser may be required.
Once you read our reports written by our team of financial analysts you will understand that we make every effort to provide informative equity research reports for interested parties at no cost.
Our Financial Analysts spend countless hours researching stocks. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges. These reports include a straightforward assessment of the company by a financial analyst who has pledged to remain free of influence when writing research reports.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Mark Bonnaci. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
A full disclaimer can be found by viewing the full analyst report.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at email@example.com. For any urgent concerns or inquiries please contact us at firstname.lastname@example.org.
©2012 PR Newswire. All Rights Reserved.